STOCK TITAN

Sarepta Therapeutics Inc - SRPT STOCK NEWS

Welcome to our dedicated news page for Sarepta Therapeutics (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sarepta Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sarepta Therapeutics's position in the market.

Rhea-AI Summary
Sarepta Therapeutics granted equity awards to 24 individuals hired in September 2023, totaling 16,575 shares and 8,575 RSUs. Options have an exercise price of $121.22 per share. Vested shares and RSUs depend on continued employment with Sarepta.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Sarepta Therapeutics announces 25 recipients of Route 79 Duchenne Scholarship Program for 2023-2024 academic year
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
-
Rhea-AI Summary
Sarepta Therapeutics to participate in fireside chat at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences
Rhea-AI Summary
Sarepta Therapeutics grants equity awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics has received Breakthrough Device Designation from the FDA for its AAVrh74 ELISA assay (CDx). The assay is used to detect antibodies to AAVrh74 capsid in human serum and is intended to identify patients eligible for treatment with Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy. Quest and Sarepta have also expanded their collaboration to develop companion diagnostics for Sarepta's gene therapies, including screening assays for muscular dystrophies. Quest will provide clinical lab testing for Sarepta as well.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
Rhea-AI Summary
Sarepta Therapeutics reported financial results for Q2 2023, with total revenues of $261.2 million, a 13% increase in net product revenues, and the first patient receiving treatment with ELEVIDYS gene therapy. The company aims to translate positive trial results to a broad label and has completed the sale of a Rare Pediatric Disease Priority Review Voucher.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) granted equity awards to 19 new employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards include options to purchase 12,550 shares of Sarepta's common stock and 6,600 restricted stock units (RSUs) at an exercise price of $108.39 per share. Vesting terms for both the options and RSUs are based on the employees' continued employment with Sarepta.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will report second quarter 2023 financial results on August 2, 2023, followed by a conference call. The event will be webcast live and a replay will be available for one year. Interested parties can register for dial-in details online.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
Rhea-AI Summary
Sarepta Therapeutics will participate in a fireside chat at Cowen's 2nd Annual RNA Therapeutics Summit on July 10, 2023. The presentation will be webcast live on Sarepta's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences
Sarepta Therapeutics Inc

Nasdaq:SRPT

SRPT Rankings

SRPT Stock Data

11.53B
89.61M
4.3%
87.88%
4.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About SRPT

sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.